Research Paper Volume 11, Issue 9 pp 2551—2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Figure 6. JNK is the downstream of miR-124/SIRT1/ROS pathway in CD133+ HCC cells. (A) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL), NAC (2 mM) and SP600125 (50 μM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Phosphorylated JNK in these cells was then detected by western blot analysis. *P<0.05 vs. cisplatin + NCO group. #P<0.05 vs. cisplatin + miR-124 group. (B) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL), NAC (2 mM) and SP600125 (50 μM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cellular ROS was then detected by flow cytometry. (C) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL), NAC (2 mM) and SP600125 (50 μM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cell viability cells was measured by MTT assays. *P<0.05 vs. cisplatin + NCO group. #P<0.05 vs. cisplatin + miR-124 group.